April 25, 2023 – Emerging from stealth mode, Radiant’s financing enables the Company to continue rapidly advancing its Multabodies that have application across multiple diseases including cancer.
Read More from FACIT backed Radiant Biotherapeutics announces closing of $8M seed round for cancer therapies
March 31, 2023 – The winning pitch for the 10th anniversary Falcons’ Fortunes pitch competition and the $100,000 Ernsting Entrepreneurship Award was delivered by Dr. Sumaiyah Rehman, co-founder and CEO of DTPx Therapeutics.
Read More from New Innovative Cancer Technology Wins 2023 Falcons’ Fortunes Pitch Competition
March 29, 2023 – FACIT announced $1.5 billion in follow-on investment attracted to its portfolio of cancer biotechnology start-ups in Ontario, a significant milestone for life science commercialization in Canada.
Read More from FACIT generates $1.5 billion in follow-on investment
March 23, 2023 – CTRL Therapeutics (“CTRL”) closed a seed financing round to develop a tumor-infiltrating lymphocyte (TIL) therapy for solid tumours. CTRL is advancing novel, non-invasive and less costly therapies for patients living with cancer.
Read More from CTRL Therapeutics, a FACIT-backed start-up, raises US$10M to develop autologous cell therapy for patients living with cancer
February 21, 2023 – This year marks the 10th anniversary of the FACIT Falcons’ Fortunes pitch competition! Be part of the audience and watch the six finalists pitch their Ontario oncology innovations.
Read More from Registration is now open for FACIT Falcons’ Fortunes pitch competition and reception
January 7, 2015 – TORONTO, ON (January 07, 2015) – FACIT and Fluorinov Pharma announced today an investment in the development of highly potent inhibitors of key bromodomain targets.
Read More from Fluorinov Pharma and FACIT Announce Investment in Breakthrough Bromodomain Inhibitors for the Treatment of Cancers
April 24, 2014 – The candidate drugs have shown excellent preliminary safety profiles, improved treatment and expect to have fewer sedative side effects.
Read More from Fluorinov, FACIT and OICR announce novel candidate drugs